Skip to content
MarketScale
‹ Back to IndustriesSciences

VPT’s Design for A New Power Converter with Gate Driving Awarded US Patent

At VPT we are constantly developing new and innovative power conversion solutions for use in avionics, military, space, and industrial applications. We are proud to announce that one of our recent breakthrough designs has earned a US patent. This is a testament to the ingenuity and expertise of our engineers who continually push the boundaries…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share

Key takeaways

01

At VPT we are constantly developing new and innovative power conversion solutions for use in avionics, military, space, and industrial applications.

02

We are proud to announce that one of our recent breakthrough designs has earned a US patent.

03

This is a testament to the ingenuity and expertise of our engineers who continually push the boundaries…

At VPT we are constantly developing new and innovative power conversion solutions for use in avionics, military, space, and industrial applications. We are proud to announce that one of our recent breakthrough designs has earned a US patent. This is a testament to the ingenuity and expertise of our engineers who continually push the boundaries of power conversion technology.

A Solution to a Common Challenge

Gate drivers utilizing isolation transformers during a short circuit event or even in the course of an ordinary shutdown sometimes face challenges, namely, the driver can lose control of the power switch causing the switch to turn on for long periods of time while the pulse-width-modulator (PWM) is commanding the driver to keep the switch off. This loss of control can often damage the power converter. VPT engineers have designed a solution to solve this problem by ensuring that the appropriate components are de-energized inside the classical dc-restore driver circuit, preventing the PWM from losing control of the power switch.

The Patent-Winning Design

VPT’s new invention includes new transformer-isolated driver designs that build upon the classical dc-restore circuit while solving the known issues with how the dc-restore circuit behaves during short circuit and shutdown events. The drive section features an innovative method of driving the power switch in cases where isolating the switch terminals from the PWM ground is desired. The design uses basic, simple parts (e.g. resistors, small discrete components, etc.) to solve the problems related to when PWM-type switching power supplies encounter fault conditions such as a short circuit across the output. It also protects the switch and the load when an ordinary shutdown or disable command is received.

Useful Applications

One advantage of this invention’s design is that it uses fewer components that are inexpensive, and common in the industry, which is crucial not only because it helps to reduce costs, but it also increases component reliability. More parts translate to a higher failure rate for the switched mode power supply. This is especially useful for military and space-borne applications where failure can be a very costly mistake.

VPT’s new patent-winning design is just the latest advancement developed by our expert engineers. Our commitment to devising new problem-solving technologies is why NASA, Lockheed Martin, Boeing, the United States Air Force, and other leading institutions depend on VPT’s power solutions for use in mission-critical devices. Learn more about our awards and achievements here.

Read more at vptpower.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512